- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04274166
Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum
The Efficacy and Safety of Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum
The purpose of this research study is to find out what effects (good and bad) secukinumab has on the subject and their pyoderma gangrenosum.
Secukinumab is a type of medicine called human monoclonal antibodies. Monoclonal antibodies are proteins that recognize and attach to other specific proteins (in this case, immune system hormones called "cytokines") that your body produces. The cytokine (a "messenger" protein in the body) that secukinumab binds to and reduces the activity of is a naturally occurring cytokine called interleukin-17A (IL-17A). IL-17A is believed to be partly responsible for inflammation (pain, swelling, redness), and researchers believe that IL-17A may cause symptoms PG.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, single center, Phase IIa study of secukinumab in the treatment of subjects diagnosed with PG. Subjects will be evaluated at Screening, Baseline (week 0), Week 1, Week 2, Week 3, Week 4, and then every 4 weeks for 24 weeks. The total duration of treatment is up to 20 weeks. Subjects may be treated for shorter durations if the lesions clear prior to week 20. Subjects will have a follow-up visit at 24 weeks, or 4 weeks after the last dose of study drug. Subjects will also have standard of care wound dressings done at each visit. Subjects will be given 300 mg of secukinumab SQ at week 0, 1, 2, 3, and 4, followed by injections every 4 weeks, for up to 20 weeks. Subjects may receive a dose increase at week 16 (if there is not at least a 25% reduction in target lesion size) to 300 mg every 2 weeks.
- Complete Blood Count (CBC), Comprehensive Metabolic panel (CMP), C- reactive protein (CRP), Erythrocyte sedimentation rate (ESR), Hepatitis panel, HIV test, Pregnancy test, and QuantiFERON gold TB test will be performed at screening. (Appendix 6)
- CBC, CMP, CRP, ESR will be performed at week 8 and week 20.
- Pain rating by Likert scale (A 10-point scale to rate the level of pain - Appendix 2), an Investigator Global Assessment (IGA) (Appendix 3), Subject Global Assessment (SGA) (Appendix 3), and Ulcer Lesion Assessment (Appendix 5) will be done at Screening, Baseline, and at Weeks 2, 4, 8, 12, 16, 20, and 24.
- Lesion photography will be done at Screening and all visits.
- Infection and adverse event assessments and concomitant medication assessments will be performed at each visit.
- Quality of life will be measured with the Dermatology Life Quality Index (DLQI) at Baseline and Week 20 (Appendix 4).
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1. Must give written informed consent. 2. Has a diagnosis of pyoderma gangrenosum, as determined by the investigator based on the following diagnostic criteria4:
a. Diagnosis requires both major criteria and at least two minor criteria i. Major criteria
- Rapid progression of a painful, necrolytic cutaneous ulcer with an irregular, violaceous, and undermined border
- Other causes of cutaneous ulceration have been excluded ii. Minor criteria
1. History suggestive of pathergy or clinical finding of cribriform scarring 2. Systemic diseases associated with PG 3. Histopathologic findings (sterile dermal neutrophilia, ± mixed inflammation, ± lymphocytic vasculitis) 4. Treatment response (rapid response to systemic steroid treatment)
3. PG global assessment of moderate to severe, with at least one ulcer measuring at least 3 cm in diameter.
4. 18 years of age or greater. 5. Must require systemic therapy for their pyoderma gangrenosum, as determined by the investigator prior to Baseline. Currently prescribed low-dose corticosteroids (≤ 10 mg/day), and other medications within one week prior to investigational drug administration, may be continued with no change in dose or frequency during the study.
Exclusion Criteria:
- Female subjects who are not postmenopausal for at least 1 year, surgically sterile, or willing to practice effective contraception during the study. Nursing mothers, pregnant women and women planning to become pregnant while on study are to be excluded.
- Current enrollment in any investigational study in which the subject is receiving any type of drug, biologic, or non-drug therapy (participation in registry-type studies is allowed).
- Serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g., pneumonia, septicemia) within the 3 months prior to the first dose of investigational drug.
- Treatment with another investigational drug or approved therapy for investigational use within 28 days prior to investigational drug administration.
- Treatment with high dose (>10 mg/day) systemic steroids (prednisone) within one week prior to investigational drug administration. Treatment with cyclosporine, thalidomide, methotrexate, mycophenolate mofetil, azathioprine, or other systemic immunosuppressant agents within the 14 days prior to investigational drug administration (requirement of a 2-week washout).
- Known HIV+, known viral hepatitis infection, known tuberculosis infection.
- Any subject with a current or history of a malignancy in the last five years (excluding treated basal cell carcinoma).
- Clinically significant abnormal laboratory measures at screening.
- Known Irritable Bowel Disease-associated PG
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental
2 s.c.
secukinumab 150 mg injections
|
secukinumab 150 mg (2 injections per dose
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy - Investigator Global Assessment (IGA)
Time Frame: Screening visit
|
Investigator Global Assessment (IGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse"
|
Screening visit
|
Efficacy - Investigator Global Assessment (IGA)
Time Frame: Change from Screening visit to Baseline visit.
|
Investigator Global Assessment (IGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse"
|
Change from Screening visit to Baseline visit.
|
Efficacy - Investigator Global Assessment (IGA)
Time Frame: Change from Baseline visit to Week 2.
|
Investigator Global Assessment (IGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse"
|
Change from Baseline visit to Week 2.
|
Efficacy - Investigator Global Assessment (IGA)
Time Frame: Change from week 2 to week 4.
|
Investigator Global Assessment (IGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse"
|
Change from week 2 to week 4.
|
Efficacy - Investigator Global Assessment (IGA)
Time Frame: Change from Week 4 to week 8.
|
Investigator Global Assessment (IGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse"
|
Change from Week 4 to week 8.
|
Efficacy - Investigator Global Assessment (IGA)
Time Frame: Change from Week 8 to week 12.
|
Investigator Global Assessment (IGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse"
|
Change from Week 8 to week 12.
|
Efficacy - Investigator Global Assessment (IGA)
Time Frame: Change from Week 12 to week 16.
|
Investigator Global Assessment (IGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse"
|
Change from Week 12 to week 16.
|
Efficacy - Investigator Global Assessment (IGA)
Time Frame: Change from Week 16 to week 20.
|
Investigator Global Assessment (IGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse"
|
Change from Week 16 to week 20.
|
Efficacy - Investigator Global Assessment (IGA)
Time Frame: Change from Week 20 to week 24.
|
Investigator Global Assessment (IGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse"
|
Change from Week 20 to week 24.
|
Efficacy - Subject Global Assessment (SGA)
Time Frame: Baseline.
|
Subject Global Assessment (SGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse"
|
Baseline.
|
Efficacy - Subject Global Assessment (SGA)
Time Frame: Change from Baseline to week 2.
|
Subject Global Assessment (SGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse"
|
Change from Baseline to week 2.
|
Efficacy - Subject Global Assessment (SGA)
Time Frame: Change from Week 2 to Week 4.
|
Subject Global Assessment (SGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse"
|
Change from Week 2 to Week 4.
|
Efficacy - Subject Global Assessment (SGA)
Time Frame: Change from Week 4 to Week 8. .
|
Subject Global Assessment (SGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse"
|
Change from Week 4 to Week 8. .
|
Efficacy - Subject Global Assessment (SGA)
Time Frame: Change from Week 8 to Week 12.
|
Subject Global Assessment (SGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse"
|
Change from Week 8 to Week 12.
|
Efficacy - Subject Global Assessment (SGA)
Time Frame: Change from Week 12 to Week 16.
|
Subject Global Assessment (SGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse"
|
Change from Week 12 to Week 16.
|
Efficacy - Subject Global Assessment (SGA)
Time Frame: Change from Week 16 to Week 20.
|
Subject Global Assessment (SGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse"
|
Change from Week 16 to Week 20.
|
Efficacy - Subject Global Assessment (SGA)
Time Frame: Change from Week 20 to Week 24.
|
Subject Global Assessment (SGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse"
|
Change from Week 20 to Week 24.
|
Efficacy - Ulcer Lesion Assessment PG Target Lesion
Time Frame: Change from Screening visit, Baseline, and at Weeks 2, 4, 8, 12, 16, 20, and 24.
|
Number of subjects achieving 50% improvement in PG lesion size
|
Change from Screening visit, Baseline, and at Weeks 2, 4, 8, 12, 16, 20, and 24.
|
Efficacy - Ulcer Lesion Assessment PG Target Lesion
Time Frame: Change from Screening visit, Baseline, and at Weeks 2, 4, 8, 12, 16, 20, and 24.
|
Number of subjects achieving resolution of inflammation with an erythema score of 0 and a border elevation of 0 on five point scales of none to very severe
|
Change from Screening visit, Baseline, and at Weeks 2, 4, 8, 12, 16, 20, and 24.
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: William W Huang, MD. MPH, Wake Forest University Health Sciences
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00063109
- Huang_IIT_CAIN457AUS24T (Other Grant/Funding Number: Novartis)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pyoderma Gangrenosum
-
SWISS BIOPHARMA MED GmbHCompletedPyoderma | Pyoderma Gangrenosum | Pyoderma Vegetans | Pyoderma Gangrenosum Surrounding Surgical StomaBelarus, Latvia
-
Dartmouth-Hitchcock Medical CenterBristol-Myers SquibbNot yet recruiting
-
Erasmus Medical CenterNot yet recruitingPyoderma Gangrenosum
-
Technical University of MunichNovartisCompletedPyoderma GangrenosumGermany
-
Wright State UniversityWake Forest University Health Sciences; Stanford UniversityWithdrawnPyoderma GangrenosumUnited States
-
Assistance Publique Hopitaux De MarseilleUnknownPyoderma GangrenosumFrance
-
University of ZurichCompleted
-
Ohio State UniversityNot yet recruitingPyoderma Gangrenosum
-
InflaRx GmbHInnovaderm Research Inc.CompletedPyoderma GangrenosumUnited States, Canada, Poland
-
Arena PharmaceuticalsTerminatedPyoderma GangrenosumAustralia, New Zealand
Clinical Trials on secukinumab 150 mg (2 injections per dose
-
Novartis PharmaceuticalsCompletedModerate to Severe Chronic Plaque-type PsoriasisUnited States, Hungary, Italy, Russian Federation, Germany, Czechia, Canada
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsCompletedModerate to Severe Plaque-type PsoriasisUnited States, Colombia, Estonia, Japan, Taiwan, Israel, Canada, Lithuania, Argentina, Latvia, Iceland, Mexico
-
Novartis PharmaceuticalsCompletedModerate to Severe Chronic Plaque-Type PsoriasisUnited States, Germany, Japan, Bulgaria, Czechia, Singapore, Switzerland, United Kingdom, Italy, France, Vietnam, Poland, Slovakia, Austria, Canada
-
Novartis PharmaceuticalsCompletedAnklyosing SpondylitisGermany, Austria, Spain, Switzerland, United Kingdom, United States, Singapore, Russian Federation, Netherlands, Italy, Finland, Czechia, Canada
-
Enimmune CorporationCompleted
-
Novartis PharmaceuticalsCompletedPsoriatic ArthritisUnited Kingdom, Germany, Italy, Spain, United States, Australia, Bulgaria, Russian Federation, Czechia, Canada, Netherlands, Switzerland, Puerto Rico
-
Novartis PharmaceuticalsCompletedModerate to Severe Palmoplantar PsoriasisBelgium, United States, Hungary, Russian Federation, Turkey, Australia, Israel, Netherlands, Portugal, Spain, United Kingdom, Norway, Slovakia, Canada, Finland
-
Novartis PharmaceuticalsCompletedAnkylosing SpondylitisGermany, Belgium, Netherlands, France, United States, Bulgaria, Italy, Russian Federation, Peru, United Kingdom, Canada, Mexico, Taiwan, Turkey
-
Novartis PharmaceuticalsCompletedPsoriatic ArthritisGermany, United Kingdom, United States, Belgium, Philippines, Singapore, Thailand, Brazil, Czech Republic, Italy, Argentina, Israel, Russian Federation, Bulgaria, Romania, Australia, Canada, Poland, Slovakia